Literature DB >> 29167553

Updated summary of genome editing technology in human cultured cells linked to human genetics studies.

Tatsuo Miyamoto1, Silvia Natsuko Akutsu2, Shinya Matsuura2.   

Abstract

Current deep-sequencing technology provides a mass of nucleotide variations associated with human genetic disorders to accelerate the identification of causative mutations. To understand the etiology of genetic disorders, reverse genetics in human cultured cells is a useful approach for modeling a disease in vitro. However, gene targeting in human cultured cells is difficult because of their low activity of homologous recombination. Engineered endonucleases enable enhancement of the local activation of DNA repair pathways at the human genome target site to rewrite the desired sequence, thereby efficiently generating disease-modeling cultured cell clones. These edited cells can be used to explore the molecular functions of a causative gene product to uncover the etiological mechanisms. The correction of mutations in patient cells using genome editing technology could contribute to the development of unique gene therapies. This technology can also be applied to screening causative mutations. Rare genetic disorders and non-exonic mutation-caused diseases remain frontier in the field of human genetics as it is difficult to validate whether the extracted nucleotide variants are mutation or polymorphism. When isogenic human cultured cells with a candidate variant reproduce the pathogenic phenotypes, it is confirmed that the variant is a causative mutation.

Entities:  

Mesh:

Year:  2017        PMID: 29167553     DOI: 10.1038/s10038-017-0349-z

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  108 in total

1.  Human genome editing as a tool to establish causality.

Authors:  Fyodor D Urnov
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-15       Impact factor: 11.205

Review 2.  CRISPR/Cas9-Directed Genome Editing of Cultured Cells.

Authors:  Luhan Yang; Joyce L Yang; Susan Byrne; Joshua Pan; George M Church
Journal:  Curr Protoc Mol Biol       Date:  2014-07-01

Review 3.  Genes involved in senescence and immortalization.

Authors:  A S Lundberg; W C Hahn; P Gupta; R A Weinberg
Journal:  Curr Opin Cell Biol       Date:  2000-12       Impact factor: 8.382

4.  Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells.

Authors:  Yunqing Ma; Jiayuan Zhang; Weijie Yin; Zhenchao Zhang; Yan Song; Xing Chang
Journal:  Nat Methods       Date:  2016-10-10       Impact factor: 28.547

5.  Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems.

Authors:  Keiji Nishida; Takayuki Arazoe; Nozomu Yachie; Satomi Banno; Mika Kakimoto; Mayura Tabata; Masao Mochizuki; Aya Miyabe; Michihiro Araki; Kiyotaka Y Hara; Zenpei Shimatani; Akihiko Kondo
Journal:  Science       Date:  2016-08-04       Impact factor: 47.728

6.  Spontaneous in vitro immortalization of breast epithelial cells from a patient with Li-Fraumeni syndrome.

Authors:  J W Shay; G Tomlinson; M A Piatyszek; L S Gollahon
Journal:  Mol Cell Biol       Date:  1995-01       Impact factor: 4.272

7.  Obligate ligation-gated recombination (ObLiGaRe): custom-designed nuclease-mediated targeted integration through nonhomologous end joining.

Authors:  Marcello Maresca; Victor Guosheng Lin; Ning Guo; Yi Yang
Journal:  Genome Res       Date:  2012-11-14       Impact factor: 9.043

8.  Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells.

Authors:  Kosuke Yusa; S Tamir Rashid; Helene Strick-Marchand; Ignacio Varela; Pei-Qi Liu; David E Paschon; Elena Miranda; Adriana Ordóñez; Nicholas R F Hannan; Foad J Rouhani; Sylvie Darche; Graeme Alexander; Stefan J Marciniak; Noemi Fusaki; Mamoru Hasegawa; Michael C Holmes; James P Di Santo; David A Lomas; Allan Bradley; Ludovic Vallier
Journal:  Nature       Date:  2011-10-12       Impact factor: 49.962

9.  Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9.

Authors:  Shota Nakade; Takuya Tsubota; Yuto Sakane; Satoshi Kume; Naoaki Sakamoto; Masanobu Obara; Takaaki Daimon; Hideki Sezutsu; Takashi Yamamoto; Tetsushi Sakuma; Ken-ichi T Suzuki
Journal:  Nat Commun       Date:  2014-11-20       Impact factor: 14.919

10.  Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system.

Authors:  Baohui Chen; Luke A Gilbert; Beth A Cimini; Joerg Schnitzbauer; Wei Zhang; Gene-Wei Li; Jason Park; Elizabeth H Blackburn; Jonathan S Weissman; Lei S Qi; Bo Huang
Journal:  Cell       Date:  2013-12-19       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.